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Susan Shurin, MD
Over the past decade, a transformation in the way
the public and policy makers approach medicine has
occurred, with emphasis upon the importance of
basing interventions upon rigorous evidence, patient-
centered and -reported outcomes, healthcare systems
that are capable of learning and improving, and
accountability of providers and institutions. All of
these laudable goals require that there be data on
short- and long-term effectiveness and toxicity—in
other words, we are supposed to know what we are
getting out, as well as what we are putting in.
This has increased the importance of research
done to address both basic scientific questions and
clinically important outcomes. Because only a small
fraction of this research will result in new drugs, diag-
nostics, or devices, the bulk of the funding for conduct
of this research comes from patient care costs and
public funders, especially the National Institutes of
Health.
There are several key challenges that face those
who design and conduct trials in rare diseases in gen-
eral, and all impact studies in hematopoietic stem cell
transplantation. Overcoming these challenges is essen-
tial for research funders to justify affect significant in-
vestment in infrastructure, particularly in times of very
stringent budget constraints. Design and conduct of
research in multiple sites is necessary to ensure mean-
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their fields of interest, but may not be expert in
the design of research studies and analysis of data.
Interdisciplinary groups must be engaged in all
stages of study design and conduct to ensure that
the scientific question is clearly enunciated, the
statistical requirements to achieve meaningful
results are clear, and the data collected and analyzed
is of high quality.
2. There are special problems in accrual of partici-
pants to these trials. The total number of eligible
patients may be small, and imposing additional
limits on eligibility (ie, creating subgroups) may
further limit the number of available participants.
3. It may not be clear how many participants are likely
to actually be available. The availability of registries
of well-characterized patients whomight be eligible
greatly facilitates conduct of studies.
4. In some circumstances, especially in nonmalignant
disorders and some pediatric conditions, other phy-
sicians may not recognize that transplantation is an
option, may envision transplantation as an unac-
ceptably toxic option, or may not know how to
make referrals or talk to patients about the options.
This has severely limited conduct of trials in hemo-
globinopathies and some other inborn conditions.
Public and private funders have multiple demands
upon their resources and are obligated to invest funds
where there will be optimal payoff in both public
health advances and scientific knowledge. Support of
infrastructure for clinical trials must facilitate the con-
duct of those studies and the rapid dissemination and
implementation of their results. Support of networks
and resources that do not complete studies that will
have high impact on the conditions under investigation
diverts funds from other research projects.
Creation of networks and clinical trials groups
requires a collaborative relationship between the
funders and the investigators and their institutions. A
well-run network brings several major benefits to
research funders, including
 Improving the speed and efficiency of the design,
launch, and conduct of clinical trials.
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into clinical trials.
 Improved prioritization, selection, support, and
completion of clinical trials.
 Providing incentives for patients and physicians to
participate in clinical trials.
 Providing a platform for engagement and training of
new investigators and of multiple disciplines in
clinical research.
The NHLBI has found several key features to
successful networks and resources.
1. An organized, motivated investigator community
capable of identifying key scientific questions and
designing studies to answer those questions. This
requires leadership, collaboration, and an ability
to set priorities, because it is unlikely that all the
important questions will be addressed.
2. A portfolio of scientific opportunities that can be
addressed through studies and will have an impact
upon meaningful aspects of patient outcome. The
benefit of a network over a series of individual
studies is its ability to conduct multiple and se-
quential studies, which requires that protocol
development be continuous, and that the dedicated
infrastructure be continuously used at full capacity.
3. Feasibility: the design of studies must be such that it
will be possible to enroll participants in the speci-
fied amount of time, submit data, and have end-
points that can be achieved within the margins of
the funding period.
a. Accrual: there must be sufficient numbers of
eligible participants who must be approached
and invited to enroll. Addressing recruitment
and referral issues early is essential; addition of
sites after studies have opened adds costs and
decreases the overall productivity of a network.
The investigator group should be self-policing
and hold its members accountable.
b. Reasonable expectations of data capture, infor-
matics, and coordinator support.
4. A strong investigator focuses on high-impact ques-
tions, creation of a culture supportive of research,
and nurturing young investigators.
In this time of profoundly limited resources for bio-
medical research, network and group clinical research
investments may play an important role [1,2,12].DESIGN OF CLINICAL STUDIES IN RARE
DISEASES
Jeff Krischer, PhD
There is no special dispensation given for conduct-
ing trials in rare diseases.Trials are held to the same eth-
ical and scientific standards across all diseases. Trialdesigns lead to sample size requirements that address
the study questions with the minimum accrual subject
to the acceptable Type 1 and 2 error rates. Hence,
they are inherently efficient in the projection of re-
quired sample sizes. Investigators have some latitude
in phrasing the study question (improvement, noninfer-
iority, difference). As well, although it is customary to
use the threshold for significance at#0.05, there is a ra-
tionale to conduct studies in limitednumbersof patients
withpower\80%.Thechoice of study endpoints along
with theminimally clinically significant effect size to be
detected also have a large impact on the requisite sample
size. Continuous endpoints generally require a smaller
sample size than discrete endpoints, and the effect size
is a major driver of target sample sizes. In some designs,
there is an inverse relationship between the numbers of
individuals to be enrolled and the planned duration of
follow-up needed to effectively power a study.
With these options in mind and the variety of
clinical trial designs available, it is possible to success-
fully conduct research in rare diseases. Because things
sometimes do not turn out as originally planned, trials
should also incorporate milestones for determining
feasibility, early emerging differences, and futility.
Methods for the latter two are readily available, but
feasibility rules need case-by-case discussion. Newer
‘‘adaptive’’ designs offer the prospect for making
mid-course corrections along the way.
The use of surrogate outcomes offers promise in
settings where outcomes are sparse or require a long
time to observe. The bar for defining an acceptable
surrogate outcome is quite high and often poorly
understood. Where there is no surrogate, the concept
of an ‘‘intermediate’’ outcome may be of value when
screening potential treatments for those to proceed
to a more definitive trial. For example, a short-term
positive result may suggest the prospect of a long-
term improvement, but the absence of a positive
short-term result may dampen enthusiasm for pro-
ceeding to the long term.
The design and successful conduct of clinical trials
in rare diseases are challenging but by nomeans unique
to the diseases or the therapeutic options [3-6].COORDINATED EFFORTS FOR SUCCESSFUL
RARE DISEASES RESEARCH AND ORPHAN
PRODUCT DEVELOPMENT
Stephen C. Groft, PharmD
There aremore than 7000 genetic and acquired rare
diseases affecting nearly 18 to 25 million Americans,
approximately 6% to 8% of the population of the
United States. A rare disease is defined as a disease
with a prevalence of\200,000 persons in the United
States. Most rare diseases affect several organ systems,
requiring multiple clinical and research disciplines to
S10 Biol Blood Marrow Transplant 18:S8-S11, 2012S. Shurin et al.be involved in conducting research and providing care
for patients. Rare diseases know no geographic, politi-
cal, or historic boundaries. The National Institutes of
Health recognizes and acknowledges the need for col-
laborative efforts of multidisciplinary research teams
and the need for new approaches to drug discovery
and development [7,8].
If there is limited or no commercial interest in
developing an intervention or a diagnostic for rare
diseases, resources and commitments from many
private and public organizations are required to
advance research discoveries leading to the develop-
ment of products for the diagnosis, prevention, or
treatment of rare diseases. A global research infrastruc-
ture of qualified investigators is required to stimulate
and coordinate research efforts by seeking ways to
provide access to clinical trials at multinational
research sites with common protocols and multidisci-
plinary research teams. A systematic coordinated
approach to research and product development is
needed and requires numerous partners from around
the world, including industry collaborators, research
investigators, federal research and regulatory agencies,
private foundations, and patient advocacy groups. Re-
markable accomplishments have been noted by using
the strengths and resources from highly motivated
partners. There are now several successful models of
patient advocacy groups directing partnerships to
reach their organizational goals of providing treat-
ments for their patients. Organizations such as the
Cystic Fibrosis Foundation, the Muscular Dystrophy
Association, Alpha-1 Foundation, Friedreich Ataxia Re-
search Association, and Parent Project for Duchenne
Muscular Dystrophy, the Progeria Research Founda-
tion, and others have expanded their traditional roles
to move the rare diseases research advances into an em-
phasis on orphan products development.
Unlike more-common diseases, gaining access to
a sufficient number of patients at any one location to
participate in clinical studies can be problematic and
requires collaborative efforts to includemultiple inves-
tigators at research sites in the United States and
around the world. These collaborations also require
investigators to adhere to common research protocols,
exchange biospecimen samples, provide medical infor-
mation to patient registries, conduct natural history
and longitudinal studies of rare diseases, and use the
resources from data monitoring and coordinating cen-
ters. Interactions initiated at family, patient, and scien-
tific conferences have often been the key link to the
establishment of multinational research investigations.The International Rare Diseases Research
Consortium (IRDiRC)
A recently established organization comprised of
research funders, patient advocacy groups, researchers,industry, and regulatory agencies have agreed to meet
the goals to deliver by the year 2020 diagnostic tests
for most rare diseases and 200 therapies for patients
affected by rare diseases [9-11]. This ambitious vision
will be realized though cooperation at the
international level. IRDiRC will develop the scientific
and policy framework to guide the research activities
and foster collaboration among the stakeholders to
systematically explore opportunities to accelerate the
development of diagnostics and therapies for rare
diseases. IRDiRC is committed to the promotion of
public data sharing, as well as the sharing of research
resources such as study designs, data analysis, data
management tools, and, to the extent possible, patient
samples. IRDiRC will work toward facilitating
international clinical trials by sharing best practices
and standard operating procedures; encouraging
harmonized policies regarding sponsorship, clinical
trial applications, ethical review, use of investigational
medicines, liability issues; and identifying existing
infrastructure programs that are working from
established research consortia/networks, biobanks/
biospecimen repositories, patient registries with
commonly accepted Common Data Elements
(CDEs), biomarkers, animal models, in vitro systems,
and genomic analyses. Additional information about
IRDiRC can be located at the following URL: http://
ec.europa.eu/research/health/medical-research/rare-
diseases/irdirc_en.html.
The Institute of Medicine (IOM) Review of Rare
Diseases Research and Orphan Products
The IOM Review of Rare Diseases Research and
Orphan Products Development and Related Activities
(ORDR) was completed in 2010 [12]. The report was
sponsored by ORDR with support from the FDA
Office of Orphan Products Development (OOPD).
The report ‘‘Rare Diseases and Orphan Products: Ac-
celerating Research and Development’’ was released
in October 2010 and can be found at http://iom.edu/
Reports/2010/Rare-Diseases-and-Orphan-Products-
Accelerating-Research-and-Development.aspx. The
Report provided an overview of elements of an inte-
grated national strategy for rare diseases research
and orphan products development. Selected IOM rec-
ommendations to the National Institutes of Health
and FDA include the following:
 Increase examination of the epidemiology, impact,
and treatment of rare diseases in the context of
assessing research and development opportunities
and activities;
 Investigate strengths and limitations of the current
development pathways for drugs and medical
devices for rare diseases;
 Provide additional support for furtherdevelopmentof
research and analysis strategies for small populations;
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funded product development studies meets FDA
standards;
 Provide a centralized preclinical development service
for rare diseases;
 Establish public–private partnerships to develop
freely available platforms for creating patient regis-
tries and biorepositories; and
 Increase capacity and flexibility for conducting reg-
ulatory reviews of all phases of clinical research on
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